Acute tumor lysis syndrome - A rare complication in the treatment of solid tumors

Onkologie

Volumn 33, Issue 10, 2010, Pages 498-499

  Coiffier, Bertrand ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CELL; CANCER THERAPY; CYTOLYSIS; EDITORIAL; HUMAN; HYPERPHOSPHATEMIA; HYPERURICEMIA; LEUKEMIA; LYMPHOMA; RISK FACTOR; SOLID TUMOR; TUMOR LYSIS SYNDROME;

ACUTE DISEASE; ACUTE KIDNEY INJURY; HUMANS; NEOPLASMS; TUMOR LYSIS SYNDROME;

EID: 77957827377     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320581     Document Type: Editorial

References (15)

1. Coiffier B, Altman A, Pui CH, Younes A, Cairo MS: Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review. J Clin Oncol 2008;26:2767-2778.
2. Cairo MS, Coiffier B, Reiter A, Younes A: Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases: an expert TLS panel consensus. Br J Haematol 2010;149:578-586.
3. Coiffier B, Riouffol C: Management of tumor lysis syndrome in adults. Expert Rev Anticancer Ther 2007;7:233-239.
4. Sezer O, Vesole DH, Singhal S, et al.: Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma 2006;7:233-235.
5. Baeksgaard L, Sorensen JB: Acute tumor lysis syndrome in solid tumors - a case report and review of the literature. Cancer Chemother Pharmacol 2003;51:187-192.
6. Mott FE, Esana A, Chakmakjian C, Herrington JD: Tumor lysis syndrome in solid tumors. Support Cancer Ther 2005;2:188-191.
7. Pinder EM, Atwal GS, Ayantunde AA, et al.: Tumour lysis syndrome occurring in a patient with metastatic gastrointestinal stromal tumour treated with glivec (imatinib mesylate, gleevec, STI571). Sarcoma 2007;2007:82012.
8. Gemici C: Tumour lysis syndrome in solid tumours. Clin Oncol (R Coll Radiol) 2006;18:773-780.
9. Mughal TI, Ejaz AA, Foringer JR, Coiffier B: An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev 2010;36:164-176.
10. Wan K, Chen Z: Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features. Onkologie 2010;33: DOI: 10.1159/000319695.
11. Michallet AS, Tartas S, Coiffier B: Optimizing management of tumor lysis syndrome in adults with hematologic malignancies. Support Cancer Ther 2005;2:159-166.
12. Drakos P, Bar-Ziv J, Catane R: Tumor lysis syndrome in nonhematologic malignancies. Report of a case and review of the literature. Am J Clin Oncol 1994;17:502-505.
13. Castro MP, VanAuken J, Spencer-Cisek P, Legha S, Sponzo RW: Acute tumor lysis syndrome associated with concurrent biochemotherapy of metastatic melanoma: a case report and review of the literature. Cancer 1999;85:1055-1059.
14. Coiffier B, Mounier N, Bologna S, et al.: Efficacy and safety of rasburicase (recombinant urate oxidase) for the prevention and treatment of hyperuricemia during induction chemotherapy of aggressive non-Hodgkin's lymphoma: results of the GRAAL1 study. J Clin Oncol 2003;21:4402-4406.
15. Hochberg J, Cairo MS: Tumor lysis syndrome: current perspective. Haematologia 2008;93:9-13.